Therefore, we propose that PGC-1α and NRF2 pathways may be also compromised in SCA17 and compounds that enhance PGC-1α and/or NRF2 expression may have potential to treat SCA17. Here, PPARGC1A is linked to spinocerebellar ataxia type 17.